Mark Smyth


Affiliation: Peter MacCallum Cancer Centre
Country: Australia


  1. Smyth M, Swann J, Kelly J, Cretney E, Yokoyama W, Diefenbach A, et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med. 2004;200:1325-35 pubmed
  2. Smyth M, Teng M, Swann J, Kyparissoudis K, Godfrey D, Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol. 2006;176:1582-7 pubmed
  3. Smyth M, Wallace M, Nutt S, Yagita H, Godfrey D, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med. 2005;201:1973-85 pubmed
    ..Overall, the data suggest that NK cell antitumor function can be enhanced greatly by strategies that are designed to expand and differentiate NK cells via DC activation of NKT cells. ..
  4. Smyth M, Swann J, Cretney E, Zerafa N, Yokoyama W, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med. 2005;202:583-8 pubmed
    ..These findings suggest an important early role for the NKG2D in controlling and shaping tumor formation. ..
  5. Smyth M, Teng M, Sharkey J, Westwood J, Haynes N, Yagita H, et al. Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res. 2008;68:3019-25 pubmed publisher
    ..These data further support the use of IL-21 in adjuvant settings where strong T cell-mediated immune responses to tumors can be generated. ..